{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T21:34:06Z","timestamp":1777584846349,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,12,30]],"date-time":"2012-12-30T00:00:00Z","timestamp":1356825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2012,12,30]],"date-time":"2012-12-30T00:00:00Z","timestamp":1356825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s10637-012-9918-3","type":"journal-article","created":{"date-parts":[[2012,12,29]],"date-time":"2012-12-29T03:05:24Z","timestamp":1356750324000},"page":"1066-1070","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Opioid growth factor (OGF) for hepatoblastoma: a novel non-toxic treatment"],"prefix":"10.1007","volume":"31","author":[{"given":"Moshe","family":"Rogosnitzky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milton J.","family":"Finegold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia J.","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian S.","family":"Zagon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,12,30]]},"reference":[{"issue":"7","key":"9918_CR1","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1634\/theoncologist.2008-0011","volume":"13","author":"JB Litten","year":"2008","unstructured":"Litten JB, Tomlinson GE (2008) Liver tumors in children. Oncologist 13(7):812\u2013820","journal-title":"Oncologist"},{"issue":"3","key":"9918_CR2","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.suc.2012.03.004","volume":"92","author":"KP Davenport","year":"2012","unstructured":"Davenport KP, Blanco FC, Sandler AD (2012) Pediatric malignancies: neuroblastoma, Wilm\u2019s tumor, hepatoblastoma, rhabdomyosarcoma, and sacroccygeal teratoma. Surg Clin N Am 92(3):745\u2013767","journal-title":"Surg Clin N Am"},{"key":"9918_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/978-3-642-14504-9_3","volume-title":"Pediatric liver tumors","author":"JM Birch","year":"2011","unstructured":"Birch JM (2011) Epidemiology of pediatric liver tumors. In: Zimmermann A, Perilongo G, Malogolowkin M, von Schweinitz D (eds) Pediatric liver tumors. Springer, Heidelberg, pp 15\u201326"},{"issue":"2","key":"9918_CR4","doi-asserted-by":"publisher","first-page":"134","DOI":"10.4174\/jkss.2011.81.2.134","volume":"81","author":"SB Moon","year":"2011","unstructured":"Moon SB, Shin HB, Seo JM, Lee SK (2011) Hepatoblastoma: 15-year experience and role of surgical treatment. J Korean Surg Soc 81(2):134\u2013140","journal-title":"J Korean Surg Soc"},{"issue":"2","key":"9918_CR5","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.cld.2011.03.011","volume":"15","author":"N Hadzic","year":"2011","unstructured":"Hadzic N, Finegold MJ (2011) Liver neoplasia in children. Clin Liver Dis 15(2):443\u2013462","journal-title":"Clin Liver Dis"},{"issue":"1","key":"9918_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1053\/j.sempedsurg.2011.10.011","volume":"21","author":"D von Schweinitz","year":"2012","unstructured":"von Schweinitz D (2012) Hepatoblastoma: recent developments in research and treatment. Semin Pediatr Surg 21(1):21\u201330","journal-title":"Semin Pediatr Surg"},{"key":"9918_CR7","doi-asserted-by":"publisher","first-page":"e938","DOI":"10.1542\/peds.2009-1597","volume":"125","author":"S Grewal","year":"2010","unstructured":"Grewal S, Merchant T, Reymond R et al (2010) Auditory late effects of childhood cancer therapy: a report from the Children\u2019s Oncology Group. Pediatrics 125:e938\u2013e950","journal-title":"Pediatrics"},{"issue":"18","key":"9918_CR8","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1016\/j.ejca.2009.06.032","volume":"45","author":"R Skinner","year":"2009","unstructured":"Skinner R, Parry A, Price L, Cole M, Craft AW, Pearson AD (2009) Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors. Eur J Cancer 45(18):3213\u20133219","journal-title":"Eur J Cancer"},{"issue":"2","key":"9918_CR9","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/pbc.22882","volume":"57","author":"B Langholz","year":"2011","unstructured":"Langholz B, Skolnik JM, Barrett JS, Renbarger J, Seibel NL, Zajicek A, Arndt CA (2011) Dactinomycin and vincristine toxicity in the treatment of childhood cancer: a retrospective study from the Children\u2019s Oncology Group. Pediatr Blood Cancer 57(2):252\u2013257","journal-title":"Pediatr Blood Cancer"},{"issue":"16","key":"9918_CR10","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.2146\/ajhp110737","volume":"69","author":"AS Lennon","year":"2012","unstructured":"Lennon AS, Norales G, Armstrong MB (2012) Cardiac arrest and possible seizure activity after vincristine injection. Am J Health Syst Pharm 69(16):1394\u20131397","journal-title":"Am J Health Syst Pharm"},{"issue":"4","key":"9918_CR11","doi-asserted-by":"publisher","first-page":"647","DOI":"10.2217\/fca.12.44","volume":"8","author":"D Harake","year":"2012","unstructured":"Harake D, Franco VI, Henkel JM, Miller TL, Lipshultz SE (2012) Cardiotoxicity in childhood cancer survivors: strategies for prevention and management. Futur Cardiol 8(4):647\u2013670","journal-title":"Futur Cardiol"},{"issue":"2","key":"9918_CR12","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1080\/jmf.17.2.157.159","volume":"17","author":"R Aviram","year":"2005","unstructured":"Aviram R, Cohen IJ, Kornreich L, Braslavski D, Meizner I (2005) Prenatal imaging of fetal hepatoblastoma. J Matern Fetal Neonatal Med 17(2):157\u2013159","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"24","key":"9918_CR13","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1200\/JCO.2010.29.3837","volume":"29","author":"MH Malogolowkin","year":"2011","unstructured":"Malogolowkin MH, Katzenstein HM, Meyers RL, Krailo MD, Rowland JM, Haas J, Finegold MJ (2011) Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology: a report from the Children\u2019s Oncology Group. J Clin Oncol 29(24):3301\u20133306","journal-title":"J Clin Oncol"},{"issue":"4","key":"9918_CR14","doi-asserted-by":"publisher","first-page":"R1154","DOI":"10.1152\/ajpregu.00414.2009","volume":"297","author":"IS Zagon","year":"2009","unstructured":"Zagon IS, Donahue RN, McLaughlin PJ (2009) Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers. Am J Physiol Regul Integr Comp Physiol 297(4):R1154\u2013R1161","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"9918_CR15","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0304-3835(03)00341-0","volume":"199","author":"PJ McLaughlin","year":"2003","unstructured":"McLaughlin PJ, Levin RJ, Zagon IS (2003) Opioid growth factor (OGF) inhibits the progression of human squamous cell carcinoma of the head and neck transplanted into nude mice. Cancer Lett 199:209\u2013217","journal-title":"Cancer Lett"},{"key":"9918_CR16","first-page":"317","volume":"33","author":"IS Zagon","year":"2008","unstructured":"Zagon IS, Kreiner S, Heslop JJ, Conway AB, Morgan CR, McLaughlin PJ (2008) Prevention and delay in progression of human pancreatic cancer by stable overexpression of the opioid growth factor receptor. Int J Oncol 33:317\u2013323","journal-title":"Int J Oncol"},{"key":"9918_CR17","doi-asserted-by":"crossref","first-page":"R780","DOI":"10.1152\/ajpregu.1996.271.3.R780","volume":"271","author":"IS Zagon","year":"1996","unstructured":"Zagon IS, Hytrek SD, Lang CM, Smith JP, McGarrity TJ, Wu Y, McLaughlin PJ (1996) Opioid growth factor ([Met5]-enkephalin) prevents the incidence and retards the growth of human colon cancer. Am J Physiol Regul Integr Comp Physiol 271:R780\u2013R786","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"9918_CR18","doi-asserted-by":"publisher","first-page":"10511","DOI":"10.1158\/0008-5472.CAN-07-1922","volume":"67","author":"F Cheng","year":"2007","unstructured":"Cheng F, Zagon IS, Verderame MF, McLaughlin PJ (2007) The opioid growth factor (OGF)-OGF receptor axis uses the p16 pathway to inhibit head and neck cancer. Cancer Res 67:10511\u201310518","journal-title":"Cancer Res"},{"key":"9918_CR19","first-page":"1059","volume":"79","author":"IS Zagon","year":"1987","unstructured":"Zagon IS, McLaughlin PJ, Goodman SR, Rhodes RE (1987) Opioid receptors and endogenous opioids in diverse human and animal cancers. J Natl Cancer Inst 79:1059\u20131065","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"9918_CR20","doi-asserted-by":"publisher","first-page":"R459","DOI":"10.1152\/ajpregu.00646.2009","volume":"298","author":"DM Avella","year":"2010","unstructured":"Avella DM, Kimchi ET, Donahue RN, Tagaram HR, McLaughlin PJ, Zagon IS, Staveley-O'Carroll KF (2010) The opioid growth factor-opioid growth factor receptor axis regulates cell proliferation of human hepatocellular cancer. Am J Physiol Regul Integr Comp Physiol 298(2):R459\u2013R466","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"2","key":"9918_CR21","first-page":"373","volume":"14","author":"PJ McLaughlin","year":"1999","unstructured":"McLaughlin PJ, Zagon IS, Skitzki J (1999) Human neuroblastoma cell growth in tissue culture is regulated by opioid growth factor. Int J Oncol 14(2):373\u2013380","journal-title":"Int J Oncol"},{"key":"9918_CR22","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00280-004-0929-4","volume":"56","author":"JR Jaglowski","year":"2005","unstructured":"Jaglowski JR, Zagon IS, Stack BC, Verderame MF, Leure-duPree AE, Manning JD, McLaughlin PJ (2005) Opioid growth factor enhances tumor growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol 56:97\u2013104","journal-title":"Cancer Chemother Pharmacol"},{"key":"9918_CR23","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s00280-005-1028-x","volume":"56","author":"IS Zagon","year":"2005","unstructured":"Zagon IS, Jaglowski JR, Verderame MF, Leure-duPree AE, Smith JP, McLaughlin PJ (2005) Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma. Cancer Chemother Pharmacol 56:510\u2013520","journal-title":"Cancer Chemother Pharmacol"},{"key":"9918_CR24","doi-asserted-by":"publisher","first-page":"110","DOI":"10.4236\/jct.2011.22013","volume":"2","author":"RN Donahue","year":"2011","unstructured":"Donahue RN, Zagon IS, McLaughlin PJ (2011) The opioid growth factor inhibits established ovarian cancer in nude mice and can be combined with taxol or cisplatin to enhance growth inhibition. J Cancer Ther 2:110\u2013124","journal-title":"J Cancer Ther"},{"issue":"9","key":"9918_CR25","first-page":"448","volume":"5","author":"N Stambuk","year":"1997","unstructured":"Stambuk N et al (1997) Peptid-M (LUPEX) immunotherapy in multiple sclerosis, optic neuritis and uveitis. Int J Thymol 5(9):448\u2013464","journal-title":"Int J Thymol"},{"key":"9918_CR26","volume-title":"Stress and immunity","author":"J Wybran","year":"1991","unstructured":"Wybran J, Plotnikoff NP (1991) Methionine-enkephalin, a new lymphokine for the treatment of ARC patients. In: Plotnikoff NJ, Murgo AJ, Faith R, Wybran J (eds) Stress and immunity. CRC Press, Boca Raton"},{"key":"9918_CR27","volume-title":"Cytokines stress & immunity","author":"B Bihari","year":"1999","unstructured":"Bihari B, Plotnikoff NP (1999) Methionine enkephalin in the treatment of AIDS-related complex. In: Plotnikoff NP, Murgo A, Faith RE, Good RA (eds) Cytokines stress & immunity. CRC Press, Boca Raton"},{"issue":"3","key":"9918_CR28","first-page":"234","volume":"40","author":"N Plotnikoff","year":"1989","unstructured":"Plotnikoff N, Wybran J (1989) Methionine-enkephalin shows promise in reducing HIV in blood. Am Fam Physician 40(3):234","journal-title":"Am Fam Physician"},{"key":"9918_CR29","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1111\/j.1749-6632.1987.tb35821.x","volume":"496","author":"NP Plotnikoff","year":"1987","unstructured":"Plotnikoff NP, Miller GC, Nimeh N, Faith RE, Murgo AJ, Wybran J (1987) Enkephalins and T-cell enhancement in normal volunteers and cancer patients. Ann N Y Acad Sci 496:608\u2013619","journal-title":"Ann N Y Acad Sci"},{"key":"9918_CR30","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/j.1749-6632.1987.tb35753.x","volume":"496","author":"J Wybran","year":"1987","unstructured":"Wybran J, Schandene L, Van Vooren JP, Vandermoten G, Latinne D, Sonnet J, De Bruyere M, Taelman H, Plotnikoff NP (1987) Imunologic properties of methionine-enkephalin, and therapeutic implications in AIDS, ARC, and cancer. Ann N Y Acad Sci 496:108\u2013114","journal-title":"Ann N Y Acad Sci"},{"key":"9918_CR31","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/j.1749-6632.1988.tb35288.x","volume":"521","author":"NP Plotnikoff","year":"1988","unstructured":"Plotnikoff NP (1988) Opioids: immunomodulators. A proposed role in cancer and aging. Ann N Y Acad Sci 521:312\u2013322","journal-title":"Ann N Y Acad Sci"},{"key":"9918_CR32","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1067\/mva.2000.107763b","volume":"32","author":"J Blebea","year":"2000","unstructured":"Blebea J, Mazo JE, Kihara TK, Vu JH, McLaughlin PJ, Atnip RG, Zagon IS (2000) Opioid growth factor modulates angiogenesis. J Vasc Surg 32:364\u2013373","journal-title":"J Vasc Surg"},{"key":"9918_CR33","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1067\/mva.2002.120042","volume":"35","author":"J Blebea","year":"2002","unstructured":"Blebea J, Vu JH, Assadnia S, McLaughlin PJ, Atnip RG, Zagon IS (2002) Differential effects of vascular growth factors on arterial and venous angiogenesis. J Vasc Surg 35:532\u2013538","journal-title":"J Vasc Surg"},{"key":"9918_CR34","first-page":"37","volume":"2","author":"JP Smith","year":"2010","unstructured":"Smith JP, Bingaman SI, Mauger DT, Harvey HH, Demers LM, Zagon IS (2010) Opioid growth factor improves clinical benefit and survival in patients with advanced pancreatic cancer. Open Access J Clin Trials 2:37\u201348","journal-title":"Open Access J Clin Trials"},{"issue":"3","key":"9918_CR35","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/00001813-200403000-00003","volume":"15","author":"JP Smith","year":"2004","unstructured":"Smith JP, Conter RL, Bingaman SI, Harvey HA, Mauger DT, Ahmad M, Demers LM, Stanley WB, McLaughlin PJ, Zagon IS (2004) Treatment of advanced pancreatic cancer with opioid growth factor: phase I. Anticancer Drugs 15(3):203\u2013209","journal-title":"Anticancer Drugs"},{"issue":"7","key":"9918_CR36","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1258\/ebm.2011.011096","volume":"236","author":"RN Donahue","year":"2011","unstructured":"Donahue RN, McLaughlin PJ, Zagon IS (2011) Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin. Exp Biol Med (Maywood) 236(7):883\u2013895","journal-title":"Exp Biol Med (Maywood)"},{"key":"9918_CR37","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/j.1572-0241.2007.01045.x","volume":"102","author":"JP Smith","year":"2007","unstructured":"Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS (2007) Low-dose naltrexone therapy improves active Crohn\u2019s disease. Am J Gastroenterol 102:820\u2013828","journal-title":"Am J Gastroenterol"},{"key":"9918_CR38","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1177\/1352458508095828","volume":"14","author":"M Gironi","year":"2008","unstructured":"Gironi M, Martinelli-Boneschi F, Sacerdote P, Solaro C, Zaffaroni M, Cavarretta R, Moiola L, Bucello S, Radaelli M, Pilato V, Rodegher M, Cursi M, Franchi S, Martinelli V, Nemni R, Comi G, Martino G (2008) A pilot trial of low dose naltrexone in primary progressive multiple sclerosis. Mult Scler 14:1076\u20131083","journal-title":"Mult Scler"},{"issue":"12","key":"9918_CR39","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/0024-3205(87)90711-9","volume":"41","author":"PJ McLaughlin","year":"1987","unstructured":"McLaughlin PJ, Zagon IS (1987) Modulation of human neuroblastoma transplanted into nude mice by endogenous opioid systems. Life Sci 41(12):1465\u20131472","journal-title":"Life Sci"},{"issue":"1\u20132","key":"9918_CR40","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/0006-8993(89)91562-X","volume":"480","author":"IS Zagon","year":"1989","unstructured":"Zagon IS, McLaughlin PJ (1989) Opioid antagonist modulation of murine neuroblastoma: a profile of cell proliferation and opioid peptides and receptors. Brain Res 480(1\u20132):16\u201328","journal-title":"Brain Res"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-012-9918-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-012-9918-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-012-9918-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-012-9918-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:35:49Z","timestamp":1678509349000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-012-9918-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,30]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["9918"],"URL":"https:\/\/doi.org\/10.1007\/s10637-012-9918-3","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,30]]},"assertion":[{"value":"26 November 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}